Orexigen, a San Diego based pharmaceutical company, announced on Monday that a new drug designed to help patients overcome obesity had passed three clinical trials and was now one step closer to FDA approval.
Contrave combines buproprion and naltrexone, two drugs used to combat a variety of mental afflictions such as depression and addiction, to reduce food cravings in obese patients. Instead of attempting to create feelings of fullness the drug works to curve the desire to eat simply as a reward or to feel better.
As much as we’d like to avoid it, the fact of the matter is that there are occasions when covering the health and fitness end of the news spectrum is going to lead us here at ShrinkGeek into the murky waters of personal politics. On the whole we strive to be as politically neutral as we can simply due to the fact that we do not wish to alienate readers who may not agree with our views. We want everyone to be healthy, regardless of where they fall in the political spectrum.
